Drug Discovery Today,
Journal Year:
2024,
Volume and Issue:
29(6), P. 104009 - 104009
Published: April 30, 2024
AI
techniques
are
making
inroads
into
the
field
of
drug
discovery.
As
a
result,
growing
number
drugs
and
vaccines
have
been
discovered
using
AI.
However,
questions
remain
about
success
these
molecules
in
clinical
trials.
To
address
questions,
we
conducted
first
analysis
pipelines
AI-native
Biotech
companies.
In
Phase
I
find
AI-discovered
an
80–90%
rate,
substantially
higher
than
historic
industry
averages.
This
suggests,
argue,
that
is
highly
capable
designing
or
identifying
with
drug-like
properties.
II
rate
∼40%,
albeit
on
limited
sample
size,
comparable
to
Our
findings
highlight
early
signs
potential
for
molecules.
The Innovation,
Journal Year:
2024,
Volume and Issue:
5(3), P. 100620 - 100620
Published: April 1, 2024
In
the
last
decade,
organoid
research
has
entered
a
golden
era,
signifying
pivotal
shift
in
biomedical
landscape.
The
year
2023
marked
milestone
with
publication
of
thousands
papers
this
arena,
reflecting
exponential
growth.
However,
amid
burgeoning
expansion,
comprehensive
and
accurate
overview
field
been
conspicuously
absent.
Our
review
is
intended
to
bridge
gap,
providing
panoramic
view
rapidly
evolving
We
meticulously
analyze
from
eight
distinctive
vantage
points,
harnessing
our
rich
experience
academic
research,
industrial
application,
clinical
practice.
present
deep
exploration
advances
technology,
underpinned
by
long-standing
involvement
arena.
narrative
traverses
historical
genesis
organoids
their
transformative
impact
across
various
sectors,
including
oncology,
toxicology,
drug
development.
delve
into
synergy
between
avant-garde
technologies
such
as
synthetic
biology
single-cell
omics
discuss
role
tailoring
personalized
medicine,
enhancing
high-throughput
screening,
constructing
physiologically
pertinent
disease
models.
analysis
reflective
discourse
provide
dive
existing
landscape
emerging
trends
technology.
spotlight
technological
innovations,
methodological
evolution,
broadening
spectrum
applications,
emphasizing
revolutionary
influence
discovery,
other
fields.
Looking
ahead,
we
cautiously
anticipate
future
developments
especially
its
potential
implications
for
patient
care,
new
avenues
research.
trust
that
will
be
an
asset
researchers,
clinicians,
patients
keen
interest
medical
strategies.
offer
broad
prospective
capabilities
encompassing
wide
range
current
applications.
summary,
attempt
field.
reflections,
summaries,
projections
might
useful
researchers
hope
contribute
shaping
trajectory
dynamic
advancing
Cancer Letters,
Journal Year:
2024,
Volume and Issue:
587, P. 216701 - 216701
Published: Feb. 16, 2024
A
new
class
of
noncoding
RNAs,
tsRNAs
are
not
only
abundant
in
humans
but
also
have
high
tissue
specificity.
Recently,
an
increasing
number
studies
explored
the
correlations
between
and
tumors,
showing
that
can
affect
biological
behaviors
tumor
cells,
such
as
proliferation,
apoptosis
metastasis,
by
modulating
protein
translation,
RNA
transcription
or
posttranscriptional
regulation.
In
addition,
widely
distributed
stably
expressed,
which
endows
them
with
broad
application
prospects
diagnosing
predicting
prognosis
they
expected
to
become
biomarkers.
However,
notably,
current
research
on
still
faces
problems
need
be
solved.
this
review,
we
describe
characteristics
well
their
unique
features
functions
tumors.
Moreover,
discuss
potential
opportunities
challenges
clinical
applications
tsRNAs.
Molecular Biomedicine,
Journal Year:
2024,
Volume and Issue:
5(1)
Published: Feb. 12, 2024
Abstract
Cancer
is
associated
with
a
high
degree
of
heterogeneity,
encompassing
both
inter-
and
intra-tumor
along
considerable
variability
in
clinical
response
to
common
treatments
across
patients.
Conventional
models
for
tumor
research,
such
as
vitro
cell
cultures
vivo
animal
models,
demonstrate
significant
limitations
that
fall
short
satisfying
the
research
requisites.
Patient-derived
organoids,
which
recapitulate
structures,
specific
functions,
molecular
characteristics,
genomics
alterations
expression
profiles
primary
tumors.
They
have
been
efficaciously
implemented
illness
portrayal,
mechanism
exploration,
high-throughput
drug
screening
assessment,
discovery
innovative
therapeutic
targets
potential
compounds,
customized
treatment
regimen
cancer
In
contrast
conventional
organoids
offer
an
intuitive,
dependable,
efficient
model
by
conserving
phenotypic,
genetic
diversity,
mutational
attributes
originating
tumor.
Nevertheless,
organoid
technology
also
confronts
bottlenecks
challenges,
how
comprehensively
reflect
microenvironment,
angiogenesis,
reduce
costs,
establish
standardized
construction
processes
while
retaining
reliability.
This
review
extensively
examines
use
techniques
fundamental
precision
medicine.
It
emphasizes
importance
patient-derived
biobanks
development,
screening,
safety
evaluation,
personalized
Additionally,
it
evaluates
application
experimental
better
understand
mechanisms
The
intent
this
explicate
significance
present
new
avenues
future
research.
Frontiers in Oncology,
Journal Year:
2025,
Volume and Issue:
15
Published: Feb. 11, 2025
Prostate
cancer
is
the
most
common
among
men
worldwide,
especially
in
those
over
65,
and
a
leading
cause
of
cancer-related
mortality.
The
disease
typically
advances
from
an
androgen-dependent
state
to
castration-resistant
prostate
(CRPC),
which
poses
significant
treatment
challenges.
androgen
receptor
(AR)
on
X
chromosome
central
driver
this
process,
activating
genes
that
govern
proliferation
survival.
Mutations
amplifications
AR
are
closely
associated
with
progression
resistance.
While
traditional
therapies
such
as
deprivation
therapy
(ADT)
antagonists
like
enzalutamide
have
been
effective,
resistance
persists
due
reactivation
signaling
through
mechanisms
ligand-independent
activation.
Recent
research
highlights
role
epigenetic
modifications
enhancing
activity
drug
tumor
microenvironment,
particularly
interactions
cancer-associated
fibroblasts
(CAFs)
tumor-associated
macrophages
(TAMs),
further
complicates
by
promoting
aggressive
behavior
immune
evasion.
Future
directions
include
developing
next-generation
antagonists,
identifying
AR-related
biomarkers
for
personalized
therapy,
exploring
combinations
checkpoint
inhibitors.
Additionally,
basal
cell-lumen-derived
organoids
provide
innovative
models
can
enhance
understanding
strategies
cancer.
Biomaterials Research,
Journal Year:
2024,
Volume and Issue:
28
Published: Jan. 1, 2024
Tissue
damage
and
functional
abnormalities
in
organs
have
become
a
considerable
clinical
challenge.
Organoids
are
often
applied
as
disease
models
drug
discovery
screening.
Indeed,
several
studies
shown
that
organoids
an
important
strategy
for
achieving
tissue
repair
biofunction
reconstruction.
In
contrast
to
established
stem
cell
therapies,
high
relevance.
However,
conventional
approaches
limited
the
application
of
regenerative
medicine.
Engineered
might
capacity
overcome
these
challenges.
Bioengineering—a
multidisciplinary
field
applies
engineering
principles
biomedicine—has
bridged
gap
between
medicine
promote
human
health.
More
specifically,
bioengineering
been
accelerate
their
translation.
this
review,
beginning
with
basic
concepts
organoids,
we
describe
strategies
cultivating
engineered
discuss
multiple
modes
create
conditions
breakthroughs
organoid
research.
Subsequently,
on
reconstruction
presented.
Finally,
highlight
limitations
challenges
hindering
utilization
applications.
Future
research
will
focus
using
advanced
tools
personalized
ACS Sensors,
Journal Year:
2024,
Volume and Issue:
9(7), P. 3466 - 3488
Published: July 11, 2024
Organ-on-a-Chip
(OOC)
technology,
which
emulates
the
physiological
environment
and
functionality
of
human
organs
on
a
microfluidic
chip,
is
undergoing
significant
technological
advancements.
Despite
its
rapid
evolution,
this
technology
also
facing
notable
challenges,
such
as
lack
vascularization,
development
multiorgan-on-a-chip
systems,
replication
body
single
chip.
The
progress
has
played
crucial
role
in
steering
OOC
toward
mimicking
microenvironment,
including
microenvironment
replication,
multiorgan
microphysiological
systems.
Additionally,
advancements
detection,
analysis,
organoid
imaging
technologies
have
enhanced
efficiency
Organs-on-Chips
(OOCs).
In
particular,
integration
artificial
intelligence
revolutionized
imaging,
significantly
enhancing
high-throughput
drug
screening.
Consequently,
review
covers
research
Human-on-a-chip,
sensors
OOCs,
latest
applications
biomedical
field.
